| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 144, Issue 12 4621-4627, Copyright © 1990 by American Association of Immunologists
ARTICLES |
GA Hashim, AA Vandenbark, AB Galang, T Diamanduros, E Carvalho, J Srinivasan, R Jones, M Vainiene, WJ Morrison and H Offner
Department of Microbiology, St. Luke's-Roosevelt Hospital, New York, NY 10025.
Recent studies from our laboratory have shown, for the first time, that a synthetic peptide from that TCR VB chain used preferentially by encephalitogenic T cells induced the formation of protective, MHC class I-restricted T cells and prevented the development of EAE in Lewis rats. In this report we 1) demonstrate that immunization with the TCR- VB8-39-59 peptide generated peptide-specific antibodies that protect against experimental autoimmune encephalomyelitis induced by either of the two distinct encephalitogenic epitopes of basic protein, and 2) characterize the production and biologic functions of rat and rabbit antibody responses to the TCR peptide. The antibodies in both species increased in titer over time, were highly specific for the immunogen by direct reaction and inhibition assays, stained only VB8+ T cells, and suppressed clinical signs and to lesser extent the number of histologic lesions of experimental autoimmune encephalomyelitis mediated by VB8+ T cells. Coupled with our previous work, these results indicate that both humoral and cellular responses to the TCR-VB8-39-59 peptide can contribute independent immunoregulatory effects on encephalitogenic T lymphocytes that use common V region genes in response to epitopes of myelin basic protein.
This article has been cited by other articles:
|
|
 |
|
  G. T. Tran, N. Carter, X. Y. He, T. S. Spicer, K. M. Plain, M. Nicolls, B. M. Hall, and S. J. Hodgkinson Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on Th1 cells that is augmented by IL-4 Int. Immunol., September 1, 2001; 13(9): 1109 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Subramanian, D. N. Bourdette, C. Corless, A. A. Vandenbark, H. Offner, and R. E. Jones T Lymphocytes Promote the Development of Bone Marrow-Derived APC in the Central Nervous System J. Immunol., January 1, 2001; 166(1): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Offner, K. Adlard, B. F. Bebo Jr., J. Schuster, G. G. Burrows, A. C. Buenafe, and A. A. Vandenbark Vaccination with BV8S2 Protein Amplifies TCR-Specific Regulation and Protection Against Experimental Autoimmune Encephalomyelitis in TCR BV8S2 Transgenic Mice J. Immunol., September 1, 1998; 161(5): 2178 - 2186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Bourdette, Y. K. Chou, R. H. Whitham, J. Buckner, H. J. Kwon, G. T. Nepom, A. Buenafe, S. A. Cooper, M. Allegretta, G. A. Hashim, et al. Immunity to T Cell Receptor Peptides in Multiple Sclerosis. III. Preferential Immunogenicity of Complementarity-Determining Region 2 Peptides from Disease-Associated T Cell Receptor BV Genes J. Immunol., July 15, 1998; 161(2): 1034 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Gaur, G Ruberti, R Haspel, J. Mayer, and C. Fathman Requirement for CD8+ cells in T cell receptor peptide-induced clonal unresponsiveness Science, January 1, 1993; 259(5091): 91 - 94. [Abstract] [PDF]
|
|
|
|
|
|
H Offner, G. Hashim, and A. Vandenbark T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis Science, January 25, 1991; 251(4992): 430 - 432. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
